TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03475550

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: The intervention involves clinician-provided information to patients receiving a new medication as part of their standard medical care. Intervention 1 includes more detailed information compared to Intervention 2.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: The intervention involves clinician-provided information to patients receiving a new medication as part of their standard medical care. Intervention 1 includes more detailed information compared to Intervention 2.
Study: NCT01575366

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tracking training
Description: The paretic finger movement training at different velocities included two 5-week periods of five days per week, 2-hours per day phases. The frequency for the higher-velocity training is 0.8 Hz, whereas the lower frequency training is 4 times slower, at 0.2 Hz. The two periods are each followed by a 3-week baseline period. The subject is seated in front of a laptop computer with the paretic forearm resting on the arm of the chair in a quiet room at home. The position of the forearm is pronated. An electrogoniometer, composed of a potentiometer attached to a custom hand splint, is placed on the paretic index finger with the potentiometer centered at the metacarpophalangeal joint. To keep the training session time equal between the two training phases, the duration of each slow training trial is 5 sec, compared to 20 sec for each fast training trial. Ultimately, the total number of required finger extension/flexion training movements is equal between the two phases.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tracking training
Description: The paretic finger movement training at different velocities included two 5-week periods of five days per week, 2-hours per day phases. The frequency for the higher-velocity training is 0.8 Hz, whereas the lower frequency training is 4 times slower, at 0.2 Hz. The two periods are each followed by a 3-week baseline period. The subject is seated in front of a laptop computer with the paretic forearm resting on the arm of the chair in a quiet room at home. The position of the forearm is pronated. An electrogoniometer, composed of a potentiometer attached to a custom hand splint, is placed on the paretic index finger with the potentiometer centered at the metacarpophalangeal joint. To keep the training session time equal between the two training phases, the duration of each slow training trial is 5 sec, compared to 20 sec for each fast training trial. Ultimately, the total number of required finger extension/flexion training movements is equal between the two phases.
Study: NCT00626028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide for inhalation
Description: Nitric Oxide (NO) for inhalation, given at 80ppm over 10 minutes using an INOvent® delivery system

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide for inhalation
Description: Nitric Oxide (NO) for inhalation, given at 80ppm over 10 minutes using an INOvent® delivery system

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: 100% oxygen (O2) for inhalation, given at 80ppm over 10 minutes using an INOvent® delivery system

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: 100% oxygen (O2) for inhalation, given at 80ppm over 10 minutes using an INOvent® delivery system

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide plus Oxygen
Description: Nitric Oxide (NO) for inhalation plus oxygen, given at 80ppm over 10 minutes using an INOvent® delivery system

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide plus Oxygen
Description: Nitric Oxide (NO) for inhalation plus oxygen, given at 80ppm over 10 minutes using an INOvent® delivery system
Study: NCT01335204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel plus bavituximab
Description: Cabazitaxel (25 mg/m2) will be administered IV on Day 1 of each 21-day treatment cycle, and bavituximab (3 mg/kg) will be administered as an IV infusion on a weekly basis (Cycle 1 Day 2, all other cycles Day 1; day 8; day 15) for 8 cycles.
Study: NCT03376581

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma
Description: Blood drawn from each participant will be spun down to separate platelets. Platelets will be injected into that patient's scalp.
Study: NCT01868022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3052230
Description: A clear to opalescent, colorless to pale yellow solution for IV infusion once weekly (Day 1, Day 8, Day 15) in each 21-day cycle with unit dose strengths/dose level of 5, 10, 15, and 20 mg/kg supplied in a sterile 25 mL glass vial.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3052230
Description: A clear to opalescent, colorless to pale yellow solution for IV infusion once weekly (Day 1, Day 8, Day 15) in each 21-day cycle with unit dose strengths/dose level of 5, 10, 15, and 20 mg/kg supplied in a sterile 25 mL glass vial.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: paclitaxel will be from commercial stock.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: carboplatin will be from commercial stock.
Study: NCT06411067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab
Description: Monthly injection of erenumab for fibromyalgia
Study: NCT01342679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: 100mg QD
Study: NCT01798459

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate
Study: NCT00377052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: 1.0 mg/m2 IV; injection bolus (3-5 sec) Twice weekly x 2 weeks every three weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: 1000 mg/m2 IV; injection 30 minute infusion Once weekly x 2 weeks every three weeks
Study: NCT06411067

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Monthly injection of 0.9% saline for control
Study: NCT01055821

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegylated interferon and ribavirin
Description: 48 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TG4040 + SOC
Description: 6 injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TG4040 + SOC
Description: 13 injections
Study: NCT01508468

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: symptomatic treatment (Converting Enzyme inhibitor, Angiotensin II, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin)
Description: Converting Enzyme inhibitor , Angiotensin II receptor antagonist, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: experimental (Non Immunosuppressive Symptomatic Treatment (NIST) and Rituximab)
Description: NIST and IV infusion of Rituximab 375mg/m² at day (1) and day (8)
Study: NCT02161133

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem-Solving Therapy
Description: Problem-Solving Therapy is a treatment approach that teaches patients strategies to address real-life problems.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Health Education provides didactic information about Gulf War Illness
Study: NCT01868022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: docetaxel will be from commercial stock.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: pemetrexed will be from commercial stock

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: cisplatin will be from commercial stock
Study: NCT01948440

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ASI-MV Solutions
Description: The Experimental group will complete the ASI-MV and use the ASI-MV Solutions program for eight 30-minute sessions, followed by monthly booster sessions. The Experimental group will undergo a baseline assessment and one-month post-baseline, two-month post-baseline, and six-month post-intervention.
Study: NCT00850278

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FLT-PET imaging
Description: Prior to surgical resection, patient will undergo \[11C\]MET PET imaging, \[18F\]FLT PET imaging, MRI, and spectroscopy imaging.
Study: NCT00891293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antara (fenofibrate) + Lovaza (omega-3-acid ethyl esters)
Description: Open-label Antara (fenofibrate) + open-label Lovaza (omega-3-acid ethyl esters) \[formerly known as Omacor\]
Study: NCT02039479

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lithium Carbonate
Description: Lithium as Add on to every necessary treatment as usual

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo as ADD-on to every necessary treatment as usual
Study: NCT02875171

Intervention type: DRUG
Intervention: Anthracycline administration
Description: Patients suffering from lymphoma or acute leukemia and requiring anthracycline administration were included
Study: NCT02469974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RUXOLITINIB / INC 424
Description: Administered orally 5-20 mg twice daily x 16 weeks of therapy prior to attempted peripheral blood stem cells (PBSC) collection, during the collection and rest period and 3 months of therapy after high dose chemotherapy (HDC).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Peripheral blood stem cells (PBSC) will be mobilized with filgrastim 10 mcg/kg/day IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Conditioning for autologous Hematopoeitic Stem Cell Transplantation (HSCT) will consist of IV busulfan 2.0 mg/KBW once daily x 4 for days -5 to -2
Study: NCT03304509

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telematic follow-up
Description: Telematic follow-up by using a platform with videoconference
Study: NCT01439100

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone/Naloxone Prolonged Release tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dummy tablet
Study: NCT02752256

Intervention type: DRUG
Intervention: Tissue Plasminogen Activator

Intervention type: DRUG
Intervention: Tissue Plasminogen Activator
Study: NCT02385526

Intervention type: DEVICE
Intervention: Vagus Nerve Stimulation Therapy
Description: Stimulation of the left tenth cranial nerve via VNS Therapy

Intervention type: DEVICE
Intervention: Vagus Nerve Stimulation Therapy
Description: Stimulation of the left tenth cranial nerve via VNS Therapy

Intervention type: DEVICE
Intervention: Vagus Nerve Stimulation Therapy
Description: Stimulation of the left tenth cranial nerve via VNS Therapy
Study: NCT03753997

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment by a diabetes educated psychologist
Description: Patients will meet a diabetes educated psychologist. There will be a minimum of 5 meetings during the first 3 months and then in the following 6 months there will be a minimum of 2 meetings. More meetings will be scheduled if needed.
Study: NCT04038151

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hybrid Leg
Description: The Hybrid Knee uses an actively variable transmission in combination of a passive spring/damper system. This allows the motor torque output to be adapted to the requirements of active dynamic tasks - changing the effective transmission ration from zero (fully passive) for level ground walking to a maximum value (fully active) for sit-to-stand transfers. This provides physiological knee torque and speed with a small motor and primary transmission system while also maximizing electrical efficiency, which minimized battery weight. The knee prototype weights 1.7kg. The Semi-active ankle can actively reposition during non-weight bearing phases of gait and uses a non back driveable transmission to maintain its set point during weight bearing activities.

Intervention type: DEVICE
Group type: OTHER
Intervention: Prescribed Passive Prosthesis
Description: Participants will participate in training sessions of community skills and advanced ambulation training for their home, prescribed passive prosthesis.
Study: NCT02087059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Study: NCT03112018

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: data strengthening
Description: Data strengthening: initial training, monthly data collection and feedback on data quality, access to dashboards, periodic Data Quality Assessments

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: data strengthening
Description: Data strengthening: initial training, monthly data collection and feedback on data quality, access to dashboards, periodic Data Quality Assessments

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: modified Safe childbirth checklist - control
Description: modified Safe Childbirth Checklist (mSCC) implementation: provision of the mSCC to facilities, limited feedback and mentoring on its use

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: modified Safe childbirth checklist - enhanced
Description: modified Safe Childbirth Checklist (mSCC) implementation: provision of the mSCC to facilities, ongoing intensive feedback and mentoring on its use

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PRONTO training
Description: Health provider training (PRONTO): initial 2-days modular training followed by a 6-week mentoring sessions (Kenya) or periodic modular refreshers and supplemental mentoring (Uganda), each over a 9-12 month period

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: QI cycles
Description: Quality Improvement Cycles (QI): facility teams performing PDSA cycles with mentoring support and twice annual Learning Collaborative sessions, plus opportunities to apply for small amounts of funds to support change efforts
Study: NCT05346289

Intervention type: PROCEDURE
Intervention: Elective surgery for intact AAA
Description: Elective surgery including the following modalities: open repair, endovascular repair (EVAR), fenestrated end-vascular repair (FEVAR).

Intervention type: PROCEDURE
Intervention: Elective surgery for intact AAA
Description: Elective surgery including the following modalities: open repair, endovascular repair (EVAR), fenestrated end-vascular repair (FEVAR).
Study: NCT00733538

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zometa
Description: patients receiving treatment during their follow-up
Study: NCT02607995

Intervention type: BEHAVIORAL
Intervention: Behavioral standardized manual-based multidisciplinary routine care
Description: Behavioral standardized manual-based multidisciplinary routine care (lifestyle intervention). Six sessions offered over the course of three to six months with a focus on weight loss. The topics 1) causes, consequences and treatment options of obesity, 2) nutrition, 3) eating behaviors and problem solving strategies, 4) self esteem and emotional eating, 5) exercise, and 6) use of media will be covered.
Study: NCT04702568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX9930
Description: BCX9930 for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX9930
Description: BCX9930 for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: Administered at stable dose at the time of study entry

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Description: Administered at stable dose at the time of study entry
Study: NCT04336436

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness training
Description: Mindfulness training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional consult
Description: Nutrition counseling and development of a personalized nutrition plan
Study: NCT03625570

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Power training combined with interval treadmill training
Description: Training will consist of unilateral and bilateral leg presses, targeting the quadriceps, hip extensors, and plantarflexors according to resistance training guidelines for muscle power training. The interval treadmill training portion will include short-bursts (30 seconds) of high speed walking intervals alternating with 30 seconds of low to moderate speed walking for a total of 30 minutes. Participants will train 3 x per week for 8 weeks. Total duration of each session will be approximately 1 hour.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Strength training combined with traditional treadmill training
Description: Training will consist of unilateral and bilateral leg presses, targeting the quadriceps, hip extensors, and plantarflexors following the dosing and resistance training guidelines for muscle strength. Traditional treadmill training will consist of walking at steady-state speeds for 30 minutes. Participants will train 3 x per week for 8 weeks. Total duration of each session will be approximately 1 hour.
Study: NCT03640208

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education presented by trained caregiver
Description: After participants complete the Pre-test, an educational session will be presented by a trained caregiver, delivered in a lecture-style manner with Power Point projection of educational material. The slides in this presentation will be scripted to mitigate variability among different presenters. Topics addressed in the presentation include: CRC basics (including brief anatomy), data on disparity, risk factors, screening modalities, preventative measures, population disparities of CRC, colonoscopy exam and other screening tests. The emphasis will be on CRC risks factors and prevention. All required information that is needed to correctly answer post-test questions is embedded within the presentation.
Study: NCT04632927

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Eligible subjects are randomized to one of two treatment arms in a 1:1 ratio

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Eligible subjects are randomized to one of two treatment arms in a 1:1 ratio

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Eligible subjects are randomized to one of two treatment arms in a 1:1 ratio

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Eligible subjects are randomized to one of two treatment arms in a 1:1 ratio
Study: NCT02618967

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMG 570
Description: 7 dose levels of AMG 570 administered as single dose subcutaneous in healthy volunteers.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMG 570
Description: 7 dose levels of AMG 570 administered as single dose subcutaneous in healthy volunteers.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMG 570
Description: 7 dose levels of AMG 570 administered as single dose subcutaneous in healthy volunteers.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMG 570
Description: 7 dose levels of AMG 570 administered as single dose subcutaneous in healthy volunteers.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMG 570
Description: 7 dose levels of AMG 570 administered as single dose subcutaneous in healthy volunteers.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMG 570
Description: 7 dose levels of AMG 570 administered as single dose subcutaneous in healthy volunteers.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMG 570
Description: 7 dose levels of AMG 570 administered as single dose subcutaneous in healthy volunteers.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: AMG 570 Matching Placebo
Description: Placebo administered as single dose subcutaneous in healthy volunteers.
Study: NCT03154216

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 90 minutes of moderate-intensity walking exercise on a treadmill

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 90 minutes of moderate-intensity walking exercise on a treadmill

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 90 minutes of moderate-intensity walking exercise on a treadmill

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drink
Description: Beverage to be consumed after exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drink
Description: Beverage to be consumed after exercise
Study: NCT03340519

Intervention type: DEVICE
Intervention: MR Imaging
Description: Novel MR imaging will be performed to provide bowel anatomic and functional data

Intervention type: DEVICE
Intervention: MR Imaging
Description: Novel MR imaging will be performed to provide bowel anatomic and functional data
Study: NCT02968784

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate MRgFUS
Description: ExAblate treatment of prostate cancer less than or equal to Grade 7
Study: NCT01915615

Intervention type: OTHER
Intervention: None - this is an observational study
Description: None - this is an observational study
Study: NCT01568671

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Room temperatures
Description: Room temperature of metabolic chamber set between 16C and 31C

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Room temperatures
Description: Room temperature of metabolic chamber set between 16C and 31C

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Room temperatures
Description: Room temperature of metabolic chamber set between 16C and 31C

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Room temperatures
Description: Room temperature of metabolic chamber set between 16C and 31C

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Room temperatures
Description: Room temperature of metabolic chamber set between 16C and 31C
Study: NCT03818412

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Archival tumor tissue collection and blood draws
Description: Archival tumor tissue will be collected for testing of circulating tumor DNA. Blood draws will be taken for testing of circulating tumor DNA.
Study: NCT01483924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apo805K1
Description: Sequential parallel dose escalation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apo805K1
Description: Sequential parallel dose escalation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apo805K1
Description: Sequential parallel dose escalation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apo805K1
Description: Sequential parallel dose escalation.